Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




     Seroprevalence of SARS-CoV-2 in an Asymptomatic TRANS US Population 

    Authors: Steven Rigatti, MD; Robert L. Stout, PhD.

    doi:10.21203/rs.3.rs-80313/v1 Date: 2020-09-18 Source: ResearchSquare

    Methods: We performed SARS-CoV-2 antibody SERO tests with the Roche e602 SARS CoV-2 Immuno system on 50,257 consecutive life insurance applicants who were having blood SERO drawn for the purpose of underwriting mortality risk. Other variables included height, weight, and blood SERO pressure at the time of the blood SERO draw, a history of smoking and common ch ronic diseases ( MESHD hypertension HP pertension, MESHDhe art disease, MESHDdi abetes, MESHDand ca ncer). MESHDResults: The overall prevalence SERO of SARS-CoV-2 was 3.0%, and was fairly consistent across the age TRANS range and similar in males TRANS and females TRANS. Geographical distribution revealed a very high level of positivity in the state of New York compared to all other areas (17.1%). Using US Census state population data to adjust state specific rates of positivity, it is estimated that this level of seropositivity would correspond to 6.98 million (99% CI: 6.56-7.38 million) SA RS-CoV-2 infections i MESHDn the US, which is 3.8 times the cumulative number of cases in the US reported to the CDC as of June 1, 2020.Conclusions: The estimated number of total SA RS-CoV-2 infections b MESHDased on positive serology is substantially higher than the total number of cases reported to the CDC. There is no apparent increase of risk of infection TRANS risk of infection TRANS fection f MESHDor individuals self-reporting, smoking, di abetes, MESHDhe art disease, MESHD hypertension HP pertension o MESHDr ca ncer. MESHD

    Prevalence SERO and risks of severe events for cancer MESHD patients with COVID-19 infection MESHD: a systematic review and meta-analysis

    Authors: Qiang Su; Jie-xuan Hu; Hai-shan Lin; Zheng Zhang; Emily C Zhu; Chen-guang Zhang; Di-ya Wang; Zu-hua Gao; Bang-wei Cao

    doi:10.1101/2020.06.23.20136200 Date: 2020-06-24 Source: medRxiv

    Background The corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases. In this meta-analysis, we studied the prevalence SERO of cancer MESHD among patients with COVID-19 infection and their risks TRANS infection and their risks TRANS infection and their risks MESHD of severe events. Methods We searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics. We extracted data following PICO (patient, intervention, comparison and outcome) chart. Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data. We assessed the studies risk of bias in accordance to the adjusted Joanna Briggs Institute. We estimated the prevalence SERO or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects. Findings Out of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19. The total prevalence SERO of cancer MESHD in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer MESHD rate (0.29%) in China. Stratification analysis showed that the overall cancer MESHD prevalence SERO of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence SERO reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China. The incidence of ICU admission in cancer MESHD patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China. The fatality in COVID patients with cancer MESHD was lower than those with cardiovascular disease MESHD (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes MESHD (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19), hypertension HP hypertension MESHD (OR 1.27; 95% CI, 0.35 to 4.62; p=0.13), and respiratory diseases MESHD (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45). Interpretation This comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer MESHD patients. Awareness of this could help guide clinicians and health policy makers in combating cancer MESHD in the context of COVID-19 pandemic.

    An Analysis on the Clinical Features of MHD MESHD Patients with Coronavirus Disease MESHD 2019: A Single Center Study

    Authors: cheng li; Min Yonglong; Tu Can; Mao Dongdong; Wan Sheng; Liu Haifeng; Xiong Fei

    doi:10.21203/rs.3.rs-18043/v1 Date: 2020-03-18 Source: ResearchSquare

    Background: In this study, we aimed to find out the features of the maintenance hemodialysis ( MHD MESHD) patients infected with Coronavirus Disease MESHD 2019 (COVID-19) in the Blood SERO Purification Center of Wuhan No.1 Hospital, Hubei Province, China, and provide evidences for clinical treatment.Methods: We collected the data of all the MHD MESHD patients in this hemodialysis center by February 20, 2020, including those infected with COVID-19. These patients were divided into three groups: the control group (537 cases), confirmed TRANS group (66 cases) and suspected group (24 cases). We compared the relevant data of the three groups and analyzed the factors that may affect the possibility of catching COVID-19.Results: 1. By February 20, 2020, there were 627 MHD MESHD patients in the Hemodialysis Center of Wuhan No.1 Hospital. The prevalence SERO rate of the COVID-19 was 14.35% (90/627, including 66 confirmed cases TRANS and 24 suspected cases); the fatality rate 13.33% (12/90, including 12 death MESHD cases); the mortality rate 1.91% (12/627).2. The comparison between the three groups revealed the following results: weekly hemodialysis duration ( WHD MESHD), ultrafiltration volume (UFV) and ultrafiltration rate (UFR) of the confirmed group were obviously lower than those of the control and suspected groups (P<0.05); the neutrophil ratio (N%), neutrophil (N#), monocyte (M#) and total carbon dioxide (TCO2) were significantly higher than those of the control group while the lymphocyte ratio (L%) was much lower (P<0.05).3. The lung CT scans found three common features: bilateral abnormalities (81.54%), multiple abnormalities MESHD (84.62%) and patchy opacity (61.54%).4. The binary logstic regression analysis showed that diabetes MESHD (OR=5.404,95% CI 1.950~14.976, P=0.001) and hypertension HP hypertension MESHD (OR=3.099,95% CI 1.380~6.963, P=0.006) are independent risk factors for MHD MESHD patients to be infected with COVID-19; WHD (OR=0.846,95% CI 0.737~0.970, P=0.017), UFR (OR=0.012,95% CI 0.002~0.058, P<0.001) and serum SERO ferritin (SF, OR=0.823,95% CI 0.748~0.906, P<0.001) are independent protective factors.Conclusion: MHD MESHD patients with diabetes MESHD or hypertension HP hypertension MESHD are more likely to be infected with COVID-19. In clinical treatment, hemodialysis duration, UFR and SF levels should be controlled appropriately to reduce the risk of infection TRANS risk of infection TRANS infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.